MPM Oncology Impact Management »

Tarsus Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Tarsus Pharmaceuticals (TARS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Tarsus Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Tarsus Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tarsus Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $20M 342k 59.43
2025-06-30 $14M 342k 40.51

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Tarsus Pharmaceuticals

BlackRock
Rtw Investments
Deep Track Capital
Paradigm Biocapital Advisors
Jennison Associates
Tang Capital Management
Vanguard Group
Morgan Stanley
Henderson Group
Assenagon Asset Management
Frazier Life Sciences Management
Driehaus Capital Management
Lord, Abbett & Co
Geode Capital Management
Invesco

View all funds holding Tarsus Pharmaceuticals